The increasing complexity of cancer chemotherapy makes it mandatory that pharmacists be familiar with these highly toxic agents. This column reviews various issues related to the preparation, dispensing, and administration of cancer chemotherapy, both commercially available and investigational.
Get full access to this article
View all access options for this article.
References
1.
National Comprehensive Cancer Network.NCCN practice guidelines in oncology: Prostate cancer. [The Complete Library of Practice Guidelines in Oncology (CD-ROM)]. Version 2001.Rockledge, PA: National Comprehensive Cancer Network; 2001.
2.
ScolieriM.J., AltmanA., ResnickM.I.Neoadjuvant hormonal ablative therapy before radical prostatectomy: A review.Is it indicated? J Urol.2000; 164: 1465–72.
3.
LyttonB.Prostate cancer: A brief history and the discovery of hormonal ablation treatment.J Urol.2001; 165: 1859–62.
4.
ByarD.P., CorleD.K.Hormone therapy for prostate cancer: Results of the Veterans Administration Cooperative Urologi-cal Research Group studies.NCI Monogr.1988; 7: 165–70.
5.
SeidenfeldJ., SamsonD.J., HasselbladV.Singleagent androgen suppression in men with advanced prostate cancer: A systematic review and meta-analysis.Ann Intern Med.2000; 132: 566–77.
6.
PotoskyA.L., KnopfK., CleggL.X.Quality-of-life outcomes after primary androgen deprivation therapy: Results from the Prostate Cancer Outcomes Study.J Clin Oncol.2001; 19: 3750–7.
7.
LabrieF., DupontA., BelangerA.Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in advanced prostate cancer: A marked improvement in response and survival.J Steroid Biochem.1985; 23: 833–41.
8.
CrawfordE.D., EisenbergerM.A., McLeodD.G.A controlled trial of leuprolide with and without flutamide in prostatic carcinoma.N Engl J Med.1989; 321: 419–24.
9.
LauferM., DenmeadeS.R., SinibaldiV.J.Complete androgen blockade for prostate cancer: What went wrong?J Urol.2000; 164: 3–9.
10.
Prostate Cancer Trialists' Collaborative Group.Maximum androgen blockade in advanced prostate cancer: An overview of the randomised trials.Lancet.2000; 355: 1491–8.
11.
SarosdyM.F., SchellhammerP.F., SharifiR.Comparison of goserelin and leuprolide in combined androgen blockade therapy.Urology.1998; 52: 82–8.
12.
TyrrellC.J., AltweinJ.E., KlippelF.A multicenter randomized trial comparing the luteinizing hormone-releasing hormone analogue goserelin acetate alone and with flutamide in the treatment of advanced prostate cancer.J Urol.1991; 146: 1321–6.
13.
BoccardoF., PaceM., RubagottiA.Goserelin acetate with or without flutamide in the treatment of patients with locally advanced or metastatic prostate cancer.Eur J Cancer.1993; 29A: 1088–93.
14.
ChatelainC., RousseauV., CosaertJ.French multicentre trial comparing Casodex (ICl 176,334) monotherapy with castration plus nilutamide in metastatic prostate cancer: A preliminary report.Eur Urol.1994; 26(Suppl 1): 10–4.
15.
DenisL.J., KeuppensF., SmithP.H.Maximal androgen blockade: Final analysis of EORTC phase III trial 30853.Eur Urol.1998; 33: 144–51.
16.
IversenP., ChristensenM.G., FriisE.A phase Ill trial of Zoladex and flutamide versus orchiectomy in the treatment of patients with advanced carcinoma of the prostate.Cancer.1990; 66: 1058–66.
17.
ThrasherJ.B., DeethsJ., BennettC.Comparative study of the clinical efficacy of two dosing regimens of flutamide.Mol Urol.2000; 4: 259–63.
